SYRE NASDAQ
Spyre Therapeutics, Inc.
1W: +8.8%
1M: +7.0%
3M: +5.0%
YTD: +204.7%
1Y: +466.2%
3Y: +711.0%
5Y: -51.4%
$93.19
+3.26 (+3.63%)
Weekly Expected Move ±5.3%
$83
$88
$93
$98
$103
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
27 relationships27
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-03-22
Earliest Filing
2024-10-15
Latest Filing
partner: 11
investor: 11
supplier: 2
target: 2
acquirer: 1
Counterparties (Filed by SYRE)
27 relationshipsCompanies named in SYRE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Paragon Therapeutics, Inc. | — | partner | Licensed IP for IL-23 antibody development in IBD | 2024-10-15 | View |
| WuXi Biologics (Hong Kong) Limited | — | supplier | Provided biologics and cell line services under novated agreements | 2024-10-15 | View |
| Parapyre Holding LLC | — | partner | Partnered with Spyre Therapeutics and Paragon to amend and restate an antibody discovery and option agreement. | 2024-05-15 | View |
| Paragon Therapeutics, Inc. | — | partner | Partnered with Spyre Therapeutics to grant exclusive licenses for antibodies targeting α4ß7 integrin and TL1A. | 2024-05-15 | View |
| Spyre Therapeutics, Inc. | SYRE | target | Target company acquired by Aeglea BioTherapeutics, Inc. | 2023-10-05 | View |
| Paragon Therapeutics, Inc. | — | partner | Counterparty to the amended antibody discovery and option agreement. | 2023-10-05 | View |
| Parapyre Holding LLC | — | partner | Entity formed by Paragon to hold equity in Spyre and receive option grants. | 2023-10-05 | View |
| Fairmount Funds Management LLC | — | investor | Major shareholder of the Company and Paragon. | 2023-10-05 | View |
| Fair Journey Biologics | — | investor | Joint venture partner with Fairmount Funds Management LLC. | 2023-10-05 | View |
| WuXi Biologics (Hong Kong) Limited | — | supplier | Provider of biologics manufacturing, testing, and cell line licensing services for the SPY001 program. | 2023-09-25 | View |
| American Stock Transfer & Trust Company LLC | AIG | partner | Acted as rights agent for Contingent Value Rights Agreement | 2023-07-27 | View |
| Immedica Pharma AB | — | acquirer | Purchased assets related to pegzilarginase program for Arginase-1 Deficiency treatment | 2023-07-27 | View |
| Spyre Therapeutics, Inc. | SYRE | partner | Entered into Agreement and Plan of Merger | 2023-07-27 | View |
| Sequoia Merger Sub II, LLC | — | partner | Wholly owned subsidiary of Aeglea used as a merger vehicle. | 2023-06-23 | View |
| Fairmount Funds Management LLC | — | investor | Healthcare investment fund where appointed directors Peter Harwin and Tomas Kiselak serve as managing members. | 2023-06-23 | View |
| Boxer Capital, LLC | — | investor | Investment firm where director Peter Harwin previously served on the investment team. | 2023-06-23 | View |
| Cogent Biosciences, Inc. | COGT | investor | Company where director Peter Harwin serves as chairman of the board. | 2023-06-23 | View |
| Paragon Therapeutics, Inc. | — | investor | Company where director Peter Harwin serves as a director. | 2023-06-23 | View |
| Apogee Therapeutics, LLC | APGE | investor | Company where director Michael Henderson serves on the board of managers. | 2023-06-23 | View |
| Apogee Therapeutics, Inc. | APGE | investor | Company where director Michael Henderson serves on the board of directors and as CEO. | 2023-06-23 | View |
| BridgeBio Pharma, Inc. | BBIO | investor | Biopharmaceutical company where director Michael Henderson previously served as Chief Business Officer. | 2023-06-23 | View |
| ARYA Sciences Acquisition Corp IV | ARYD | investor | Special purpose acquisition company where director Michael Henderson serves on the board of directors. | 2023-06-23 | View |
| Aspen Merger Sub I, Inc. | ASPU | partner | Wholly owned subsidiary of Aeglea used as a merger vehicle. | 2023-06-23 | View |
| Spyre Therapeutics, Inc. | SYRE | target | Target company acquired by Aeglea BioTherapeutics, Inc. in a merger agreement. | 2023-06-23 | View |
| Viridian Therapeutics, Inc. | VRDN | investor | Company where director Peter Harwin serves on the board. | 2023-06-23 | View |
| JonesTrading Institutional Services LLC | — | partner | Agent for Capital on DemandTM Sales Agreement to sell common stock | 2022-05-20 | View |
| Immedica Pharma AB | — | partner | License agreement for commercialization of pegzilarginase in specific international markets | 2021-03-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-25 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-15 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-05-29 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-16 | Material Agreement; Exhibits | Agreement | View |
| 2026-04-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-13 | Earnings Release; Other Events | View | |
| 2026-02-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-10-15 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-10-14 | Results of Operations and Financial Condition | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-02 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-06 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR